摘要
目的:探讨康柏西普和雷珠单抗治疗湿性年龄相关性黄斑变性的临床效果。方法:收治湿性年龄相关性黄斑变性患者40例,分为对照组和研究组。对照组采用康柏西普治疗,研究组采用雷珠单抗治疗,比较两组治疗效果。结果:两组治疗后的BCVA、OCT数值差异无统计学意义(P>0.05);研究组注射次数少于对照组(P<0.05)。结论:在治疗湿性年龄相关性黄斑变性过程中,康柏西普和雷珠单抗的治疗效果相当,但相对而言,雷珠单抗的注射次数更少,具有一定的治疗优势性。
Objective:To explore the clinical effect of conbercept and rezumumab in the treatment of wet age-related macular degeneration.Methods:40 patients with wet age-related macular degeneration were chosen,and they were divided into the control group and the study group.The control group was treated with conbercept,and the study group was treated with rezumumab.We compared the therapeutic effects of two groups.Results:There was no significant difference in the value of BCVA and OCT between groups after treatment(P>0.05).The number of injections in the study group was less than that of the control group(P<0.05).Conclusion:In the treatment of wet age-related macular degeneration,the therapeutic effects of conbercept and rezumumab were quite effective,but relative,the number of injection of rezumumab was less,and it had a certain therapeutic advantage.
作者
李磊
李凌
马雪英
张蓉
秦志宏
Li Lei;Li Ling;Ma Xueying;Zhang Rong;Qin Zhihong(Ophthalmology Department,the People's Hospital of Qinghai Province 810007)
出处
《中国社区医师》
2018年第9期14-15,共2页
Chinese Community Doctors
